bioRxivImmunology
Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees
P. Yadav, G. N. Sapkal, P. Abraham, R. Ella, G. Deshpande, D. Y. Patil, D. Nyayanit, N. Gupta, R. R. Sahay, A. M. Shete, S. Panda, B. Bhargava, V. K. Mohan
Abstract
The drastic rise in the number of cases in Maharashtra, India has created a matter of concern for public health experts. Twelve isolates of VUI lineage B.1.617 were propagated in VeroCCL81 cells and characterized. Convalescent sera of the COVID-19 cases and recipients of BBV152 (Covaxin) were able to neutralize VUI B.1.617.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
P. D. Yadav, G. Sapkal, … B. Bhargava·bioRxiv·Jun 5, 2021
- Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152
Pragya Dhruv Yadav, Rima Rakeshkumar Sahay, … Balram Bhargava·Journal of Travel MedicinePeer-reviewed·Sep 21, 2021
- Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1
P. Yadav, G. N. Sapkal, … B. Bhargava·bioRxiv·May 12, 2021
- Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant
V.-V. Edara, L. Lai, … M. Suthar·bioRxiv·May 9, 2021
- Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
G. Sapkal, P. Yadav, … B. Bhargava·bioRxiv·Apr 30, 2021
- Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum
Gajanan N. Sapkal, Pragya Dhruv Yadav, … Balram Bhargava·bioRxiv·Jan 26, 2021